Cargando…
Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice
OBJECTIVES: Direct-acting antivirals have shown high efficacy in all hepatitis C virus (HCV) genotypes, but genotype 3 (G3) treatments continue to be a challenge, mainly in cirrhotic patients. The aim of this study is to analyse effectiveness and safety of daclatasvir associated with sofosbuvir with...
Autores principales: | Margusino-Framiñán, Luis, Cid-Silva, Purificación, Mena-de-Cea, Álvaro, Rodríguez-Osorio, Iria, Pernas-Souto, Berta, Delgado-Blanco, Manuel, Pertega-Díaz, Sonia, Martín-Herranz, Isabel, Castro-Iglesias, Ángeles |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedad Española de Quimioterapia
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441991/ https://www.ncbi.nlm.nih.gov/pubmed/30761823 |
Ejemplares similares
-
Late HIV Diagnosis but Earlier Antiretroviral Treatment Initiation in Northwest Spain: Impact of Current Treatment Guidelines
por: Cid-Silva, Purificación, et al.
Publicado: (2019) -
Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
por: McEwan, Phil, et al.
Publicado: (2017) -
Sofosbuvir and daclatasvir
por: Hessel, Marleen H. M., et al.
Publicado: (2016) -
High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients
por: Pellicelli, Adriano, et al.
Publicado: (2020) -
Circulating microRNAs as predictors of response to sofosbuvir + daclatasvir + ribavirin in in HCV genotype-4 Egyptian patients
por: Hassuna, Noha Anwar, et al.
Publicado: (2022)